HARMONi-GI3

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Oct 17, 2025 → Oct 25, 2026

Cited window

Oct 20, 2025 → Sep 19, 2026

Retrieved

Oct 29, 2026

Title

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer

Registry

NCT07228832

Study IDs

SMT112-3005

Sponsor

Summit Therapeutics

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

600 estimated

Start

2025-11-18 actual

Primary completion

2028-05-31 estimated

Primary endpoint

PFS by IRRC based on RECIST v1.1

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The public posts reviewed do not establish consensus, the prevalence of a view among HCPs or how clinicians are treating patients in routine practice.
• –Some authors have confirmed physician identities, while others have unverified identities or an unresolved clinical role. An organizational relay and commercial commentary should not be counted as additional independent HCP judgments.
• –Discussion using unnamed references or different wording may be absent, and some passages were not fully assessed for clinician views. An aspect with no commentary therefore describes only what was identified in the sources reviewed for this edition.
• –No full protocol or results publication for the exact trial was available among the sources reviewed, and exact product-label information was unavailable. Detailed endpoint specifications, approved-use questions and comparative outcomes cannot be settled from these comments.
• –The reported colorectal efficacy and safety figures are phase II evidence, not HARMONi-GI3 results. Lung-cancer studies are invoked as motivation, not as evidence of efficacy in metastatic colorectal cancer.
• –Post dates identify when comments were published, not when a session, readout or site activation occurred. They do not establish changes of mind or disagreement across settings.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "HARMONi-GI3" (NCT07228832), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "harmoni-gi3-07228832". If you cannot make requests, read https://www.erudio.com/reports/harmoni-gi3-nct07228832.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT07228832", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct07228832 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/harmoni-gi3-nct07228832.json
curl https://www.erudio.com/reports/harmoni-gi3-nct07228832.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "harmoni-gi3-07228832" })